Psoriasis
Frank Oliver Nestle, Daniel H. Kaplan, Jonathan Barker · New England Journal of Medicine · 2009
Cited by 2,786 works. doi:10.1056/nejmra0804595 Open-access PDF
Authors
References
- Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
- Risk of Myocardial Infarction in Patients With Psoriasis
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- Pathogenesis and therapy of psoriasis
- Pathogenesis and clinical features of psoriasis
- The Natural History of Psoriasis in 5,600 Patients
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- Psoriasis
- Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
- A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk Genes